Opportunities for early dialogue with the EMA and HTA bodies. Optimizing product development to ensure commercial success

Published on: Nov 30th, 2017

Early engagement and scientific advice with European Medicines Agency (EMA) is a key driver to faster and more often, successful registration. In addition, early discussion with HTA bodies and other stakeholders can be critical towards early patient access and commercial success in Europe. There is growing interest in the EMA/EUnetHTA Parallel Consultation Process. In this webinar, Florence Bine-Scheck, Senior Medical Director and Carole Jones, Director of Market Access at VCLS will share their insights through some case studies on the importance of seeking parallel HTA-EMA advice and how to be well prepared for the meeting to ensure both successful  registration and commercial success.

Key learning objectives:

• Understand the difference between the European Medicines Agency (EMA) Scientific Advice and the EMA/EUnetHTA Parallel Consultation procedure
• Weigh the pros and cons when considering the choice of an EMA/EUnetHTA Parallel Consultation procedure
• Steps to a well-prepared meeting: how to best plan for an EMA/EUnetHTA Parallel Consultation procedure and how to ask the right questions to obtain relevant information out of the process

Keywords:

European Medicines Agency (EMA), Healthcare Technology Assessment (HTA) bodies, Parallel Scientific Advice, EMA/EUnetHTA Parallel Consultation, Market Access

SAMPLE OF THE WEBINAR

VCLS Webinar – Opportunities for early dialogue with the EMA and HTA bodies

FEATURED SPEAKERS

Florence Bine-Scheck, MD

Senior Medical Director